Integra LifeSciences shareholders approve 2.2M share increase in equity plan; chairman transitions to non-executive role

INTEGRA LIFESCIENCES HOLDINGS CORP

Stockholders approved Amendment No. 2 to increase shares under equity plan by 2.2M, to 20.7M total.
All nine director nominees elected at May 9 annual meeting; PwC ratified as auditor; say-on-pay approved.
Board approved transition of Dr. Essig from Executive Chairman to non-executive Chairman effective July 1, 2025; no disagreement.
Plan amendment eliminates provision allowing shares withheld for taxes to be returned to the plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.